The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
1 Year | 5 Year | 5 Year Annualized | Since IPO | |
---|---|---|---|---|
ONTX | -44.77% | -97.46% | -52.05% | -100% |
S&P | +15.06% | +95.03% | +14.29% | +298% |
Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. It focuses on discovering and developing small molecule drug candidates to treat cancer. The company was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA.
Investors are eager to hear more about the biotech's experimental cancer treatments.
Q2 2025 | YOY Change | |
---|---|---|
Revenue | $2.73M | 4694.7% |
Gross Profit | $2.73M | 5054.7% |
Gross Margin | 99.96% | 7.0% |
Market Cap | $8.24M | -12.6% |
Market Cap / Employee | $1.18M | 0.0% |
Employees | 7 | -58.8% |
Net Income | -$0.63M | 99.5% |
EBITDA | -$1.25M | 78.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
Q2 2025 | YOY Change | |
---|---|---|
Net Cash | $13.08M | -22.5% |
Accounts Receivable | $1.32M | 7250.0% |
Inventory | 0 | 0.0% |
Q2 2025 | YOY Change | |
---|---|---|
Long Term Debt | $0.00M | 0.0% |
Short Term Debt | $0.00M | 0.0% |
Q2 2025 | YOY Change | |
---|---|---|
Return On Assets | 512.48% | 1070.1% |
Return On Invested Capital | -102.83% | 71.7% |
Q2 2025 | YOY Change | |
---|---|---|
Free Cash Flow | -$5.98M | 39.3% |
Operating Free Cash Flow | -$5.98M | 39.3% |
Metric | Q2 2025 | YoY Change | |||
---|---|---|---|---|---|
Price to Earnings | 0.09 | - | |||
Price to Book | -0.06 | -13.22 | -0.27 | 1.25 | -20.05% |
Price to Sales | 25.02 | 143.44 | 73.10 | 2.97 | -94.07% |
Price to Tangible Book Value | -0.06 | -13.22 | -0.27 | 1.25 | -20.05% |
Enterprise Value to EBITDA | -0.03 | -0.37 | -0.13 | 3.58 | -119.84% |
Return on Equity | -1096.5% | -2255.4% | -576.1% | 1224.3% | -1074.08% |
Total Debt | $0.00M | $0.00M | $0.00M | $0.00M | - |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.